{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:55:50Z","timestamp":1791932150164,"version":"4.3.4"},"reference-count":35,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471112"],"award-info":[{"award-number":["82471112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aims to evaluate the efficacy and safety of intravenous (IV) tocilizumab (TCZ) in the treatment of Graves\u2019 ophthalmopathy (GO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search was conducted across the Web of Science, PubMed, Embase, Cochrane Library, World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov databases from inception to April 2024. Randomized controlled trials and cohort studies that used IV TCZ for treating GO were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve studies encompassing 219 patients with active, steroid-resistant GO were analyzed. The meta-analysis demonstrated significant improvements in Clinical Activity Score (CAS) response (effect size [ES] = 0.98; 95% confidence interval [CI], 0.93-1.00), proptosis response (ES = 0.50; 95% CI, 0.27-0.73), and diplopia response (ES = 0.48; 95% CI, 0.24-0.74). The ES for adverse events was 0.27 (95% CI, 0.22-0.33), with only 3 severe cases necessitating treatment discontinuation, and a low reactivation rate (ES = 0.01; 95% CI, 0.00-0.04). TCZ treatment led to a mean CAS reduction of 4.60 points (95% CI, 3.88-5.32) across 10 studies, a mean proptosis reduction of 2.04\u2005mm (95% CI, 1.42-2.65) across 7 studies, and a mean decrease in TSH receptor antibodies levels of 10.62\u2005IU (95% CI, 4.67-10.62) across 5 studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis provides robust evidence supporting the efficacy and safety of IV TCZ in patients with GO who are resistant to glucocorticoid therapy. The results highlight TCZ's comparable efficacy to glucocorticoids and suggest that TCZ could significantly expand clinical management options for GO. In the future, more high-quality, large-scale randomized controlled trials are still needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae711","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T14:35:30Z","timestamp":1728916530000},"page":"e886-e896","source":"Crossref","is-referenced-by-count":17,"title":["The Efficacy and Safety of Intravenous Tocilizumab to Treat Graves\u2019 Ophthalmopathy: A Systematic Review and Single-arm Meta-analysis"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3521-3629","authenticated-orcid":false,"given":"Aimin","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Peking University , Beijing, 100000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Peking University , Beijing, 100000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University Peoples\u2019 Hospital, Peking University , Beijing, 100000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2080-1414","authenticated-orcid":false,"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Peking University , Beijing, 100000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"issue":"8","key":"2025021815503520200_dgae711-B1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"2025021815503520200_dgae711-B2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000266782","article-title":"Clinical presentation of Graves\u2019 ophthalmopathy","volume":"21","author":"Wiersinga","year":"1989","journal-title":"Ophthalmic Res"},{"issue":"2","key":"2025021815503520200_dgae711-B3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ecl.2021.12.004","article-title":"2022 update on clinical management of Graves disease and thyroid eye disease","volume":"51","author":"Hoang","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"2025021815503520200_dgae711-B4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jfma.2013.12.002","article-title":"Assessing quality of life in Taiwanese patients with Graves\u2019 ophthalmopathy","volume":"114","author":"Lin","year":"2015","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"2025021815503520200_dgae711-B5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","article-title":"Quality of life in patients with chronic thyroid eye disease in the United States","volume":"10","author":"Cockerham","year":"2021","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"2025021815503520200_dgae711-B6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025021815503520200_dgae711-B7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025021815503520200_dgae711-B8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025021815503520200_dgae711-B9","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025021815503520200_dgae711-B10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.23736\/S1824-4785.21.03350-1","article-title":"Graves\u2019 orbitopathy: a multidisciplinary approach","volume":"65","author":"Limone","year":"2021","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"4","key":"2025021815503520200_dgae711-B11","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2025021815503520200_dgae711-B12","doi-asserted-by":"publisher","DOI":"10.18170\/DVN\/PVRZGY","volume-title":"Supplementary Data from a Meta-Analysis of Tolizumab in the Treatment of Thyroid Eye Disease","author":"Aimin","year":"2024"},{"issue":"2","key":"2025021815503520200_dgae711-B13","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/09273948.2020.1808688","article-title":"Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves\u2019 orbitopathy","volume":"30","author":"Bennedja\u00ef","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"2025021815503520200_dgae711-B14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10792-024-03117-6","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study","volume":"44","author":"Lee","year":"2024","journal-title":"Int Ophthalmol"},{"key":"2025021815503520200_dgae711-B15","doi-asserted-by":"crossref","first-page":"1186105","DOI":"10.3389\/fendo.2023.1186105","article-title":"Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study","volume":"14","author":"Boutzios","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2025021815503520200_dgae711-B16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant Graves\u2019 orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"9","key":"2025021815503520200_dgae711-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9092816","article-title":"Anti-il-6 receptor tocilizumab in refractory graves\u2019 orbitopathy: national multicenter observational study of 48 patients","volume":"9","author":"S\u00e1nchez-Bilbao","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"2025021815503520200_dgae711-B18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14655","article-title":"Long-term outcomes in corticosteroid-refractory Graves\u2019 orbitopathy treated with tocilizumab","volume":"97","author":"Moi","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025021815503520200_dgae711-B19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/01676830.2022.2119262","article-title":"Treatment of corticosteroid-resistant Graves\u2019 orbitopathy with tocilizumab: a single-centre prospective study","volume":"42","author":"Dorado Cortez","year":"2023","journal-title":"Orbit"},{"issue":"10","key":"2025021815503520200_dgae711-B20","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/thy.2023.0167","article-title":"Medical therapy in patients with moderate to severe, steroid-resistant, thyroid eye disease","volume":"33","author":"Toro-Tobon","year":"2023","journal-title":"Thyroid"},{"issue":"4","key":"2025021815503520200_dgae711-B21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/jcm10040706","article-title":"Steroid-resistant Graves\u2019 orbitopathy treated with tocilizumab in real-world clinical practice: a 9-year single-center experience","volume":"10","author":"P\u00e9rez-Moreiras","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"2025021815503520200_dgae711-B22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IOP.0000000000002027","article-title":"Tocilizumab for the management of thyroid-associated orbitopathy","volume":"38","author":"Smith","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"2025021815503520200_dgae711-B23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.medcli.2022.05.007","article-title":"Outcome of tocilizumab treatment in corticosteroid-resistant thyroid eye disease","volume":"160","author":"Pamp\u00edn-S\u00e1nchez","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"2025021815503520200_dgae711-B24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"2025021815503520200_dgae711-B25","doi-asserted-by":"crossref","first-page":"7453260","DOI":"10.1155\/2019\/7453260","article-title":"Immunological aspects of Graves\u2019 ophthalmopathy","volume":"2019","author":"\u0141acheta","year":"2019","journal-title":"Biomed Res Int"},{"issue":"5","key":"2025021815503520200_dgae711-B26","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1210\/jc.2011-2890","article-title":"A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves\u2019 orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody","volume":"97","author":"Kumar","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815503520200_dgae711-B27","doi-asserted-by":"crossref","first-page":"739994","DOI":"10.3389\/fendo.2021.739994","article-title":"Orbital signaling in Graves\u2019 orbitopathy","volume":"12","author":"Draman","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2025021815503520200_dgae711-B28","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025021815503520200_dgae711-B29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1530\/EJE-11-0779","article-title":"Fatal and non-fatal adverse events of glucocorticoid therapy for Graves\u2019 orbitopathy: a questionnaire survey among members of the European Thyroid Association","volume":"166","author":"Marcocci","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025021815503520200_dgae711-B30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bjophthalmol-2020-316051","article-title":"Medical treatment in thyroid eye disease in 2020","volume":"105","author":"Khong","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"2025021815503520200_dgae711-B31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/08916939708996275","article-title":"High circulating IL-6 level in Graves\u2019 ophthalmopathy","volume":"25","author":"Moln\u00e1r","year":"1997","journal-title":"Autoimmunity"},{"issue":"8","key":"2025021815503520200_dgae711-B32","first-page":"2976","article-title":"Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves\u2019 disease","volume":"81","author":"Salvi","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025021815503520200_dgae711-B33","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.4049\/jimmunol.175.2.1310","article-title":"IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy","volume":"175","author":"Chen","year":"2005","journal-title":"J Immunol"},{"key":"2025021815503520200_dgae711-B34","doi-asserted-by":"crossref","first-page":"1160936","DOI":"10.3389\/fendo.2023.1160936","article-title":"Efficacy and safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves\u2019 ophthalmopathy: a systematic review and meta-analysis","volume":"14","author":"Hu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2025021815503520200_dgae711-B35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000356042","article-title":"Graves\u2019 orbitopathy: imperfect treatments for a rare disease","volume":"2","author":"Bartalena","year":"2013","journal-title":"Eur Thyroid J"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae711\/60414455\/dgae711.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e886\/60414455\/dgae711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e886\/60414455\/dgae711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:11:35Z","timestamp":1739877095000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/3\/e886\/7821525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae711","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,14]]}}}